MY197561A - Composition for increasing expression of pgc-1? - Google Patents
Composition for increasing expression of pgc-1?Info
- Publication number
- MY197561A MY197561A MYPI2018702452A MYPI2018702452A MY197561A MY 197561 A MY197561 A MY 197561A MY PI2018702452 A MYPI2018702452 A MY PI2018702452A MY PI2018702452 A MYPI2018702452 A MY PI2018702452A MY 197561 A MY197561 A MY 197561A
- Authority
- MY
- Malaysia
- Prior art keywords
- composition
- pgc
- increasing expression
- expression
- solvate
- Prior art date
Links
- 102000017946 PGC-1 Human genes 0.000 abstract 1
- 108700038399 PGC-1 Proteins 0.000 abstract 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003081 coactivator Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/04—Disaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160004383 | 2016-01-13 | ||
| PCT/KR2017/000505 WO2017123066A1 (ko) | 2016-01-13 | 2017-01-13 | Pgc-1알파의 발현을 증가시키는 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY197561A true MY197561A (en) | 2023-06-23 |
Family
ID=59311711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2018702452A MY197561A (en) | 2016-01-13 | 2017-01-13 | Composition for increasing expression of pgc-1? |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190030053A1 (enExample) |
| EP (2) | EP3403655B1 (enExample) |
| JP (3) | JP7125348B2 (enExample) |
| KR (3) | KR20180099885A (enExample) |
| CN (3) | CN120643579A (enExample) |
| CA (2) | CA3010338C (enExample) |
| ES (1) | ES2946945T3 (enExample) |
| HK (1) | HK1257689A1 (enExample) |
| MX (2) | MX389553B (enExample) |
| MY (1) | MY197561A (enExample) |
| SG (1) | SG11201805791RA (enExample) |
| WO (1) | WO2017123066A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3498282A1 (en) * | 2017-12-12 | 2019-06-19 | Rheinische Friedrich-Wilhelms-Universität Bonn | 6'-sialyllactose for use in the treatment of hearing loss |
| US11234992B2 (en) * | 2018-02-28 | 2022-02-01 | The Regents Of The University Of California | Methods and therapies for treating atherosclerosis and/or hyperlipidemia using oligosaccharides |
| AU2020230410A1 (en) * | 2019-03-05 | 2021-09-02 | Société des Produits Nestlé S.A. | A nutritional composition for use to enhance executive function |
| MX2021010289A (es) * | 2019-03-05 | 2022-02-10 | Glycom As | Oligosacaridos de leche humana para uso en el mejoramiento de la funcion ejecutiva. |
| JP2021038147A (ja) * | 2019-08-30 | 2021-03-11 | 国立大学法人 鹿児島大学 | ミトコンドリア生合成促進剤 |
| KR102186761B1 (ko) * | 2020-06-03 | 2020-12-04 | 옙바이오 주식회사 | 2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물을 포함하는 파킨슨병 예방 또는 치료용 약학적 조성물 |
| GB202114190D0 (en) * | 2021-10-04 | 2021-11-17 | Mjn Us Holdings Llc | Compositions for preventing and/or treating demyelination |
| CN121100111A (zh) * | 2023-06-02 | 2025-12-09 | 兹杜斯生命科学有限公司 | 用于肌萎缩侧索硬化(als)的治疗 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5164374A (en) * | 1990-12-17 | 1992-11-17 | Monsanto Company | Use of oligosaccharides for treatment of arthritis |
| JPH07258093A (ja) * | 1994-03-23 | 1995-10-09 | Morinaga Milk Ind Co Ltd | 神経成長因子様剤 |
| KR101116864B1 (ko) * | 2008-08-01 | 2012-02-29 | 주식회사 베네비오 | 고지혈증, 지방간 또는 비만의 예방 또는 치료용 조성물 |
| KR101112051B1 (ko) * | 2009-04-09 | 2012-02-14 | 주식회사 베네비오 | 비후성 반흔 또는 켈로이드 예방 또는 치료용 조성물 |
| KR20110092602A (ko) * | 2010-02-09 | 2011-08-18 | 주식회사 베네비오 | 플라스미노겐 활성 억제인자-1의 억제제 |
| SG10202110501RA (en) * | 2010-12-31 | 2021-11-29 | Abbott Lab | Methods For Decreasing The Incidence Of Necrotizing Enterocolitis In Infants, Toddlers, Or Children Using Human Milk Oligosaccharides |
| DE112013004483T5 (de) * | 2012-09-14 | 2015-06-03 | Robert Bosch Gmbh | Überprüfung einer Vorrichtung unter Verwenden eines Versperrens einer akustischen Öffnung |
| TW201438719A (zh) * | 2012-12-18 | 2014-10-16 | Abbott Lab | 改善壓力症狀之母乳寡糖 |
| WO2014100191A1 (en) * | 2012-12-18 | 2014-06-26 | Abbott Laboratories | Nutritional compositions comprising neuroprotective dietary oligosaccharides |
| DE102013208103A1 (de) | 2013-05-03 | 2014-11-06 | Siemens Aktiengesellschaft | Röntgenquelle und bildgebendes System |
| WO2016145628A1 (en) * | 2015-03-18 | 2016-09-22 | Nestec S.A. | Composition comprising siallyllactose for use in enhancing learning skills and memory function |
-
2017
- 2017-01-13 MY MYPI2018702452A patent/MY197561A/en unknown
- 2017-01-13 US US16/069,972 patent/US20190030053A1/en active Pending
- 2017-01-13 CN CN202511095571.2A patent/CN120643579A/zh active Pending
- 2017-01-13 CA CA3010338A patent/CA3010338C/en active Active
- 2017-01-13 CN CN201780006641.XA patent/CN108472305A/zh active Pending
- 2017-01-13 EP EP17738695.0A patent/EP3403655B1/en active Active
- 2017-01-13 CA CA3203927A patent/CA3203927A1/en active Pending
- 2017-01-13 JP JP2018536439A patent/JP7125348B2/ja active Active
- 2017-01-13 EP EP21154787.2A patent/EP3845233A1/en active Pending
- 2017-01-13 KR KR1020187023369A patent/KR20180099885A/ko not_active Ceased
- 2017-01-13 KR KR1020217017487A patent/KR20210079376A/ko not_active Ceased
- 2017-01-13 HK HK19100055.1A patent/HK1257689A1/zh unknown
- 2017-01-13 KR KR1020237023071A patent/KR102771814B1/ko active Active
- 2017-01-13 WO PCT/KR2017/000505 patent/WO2017123066A1/ko not_active Ceased
- 2017-01-13 MX MX2018008671A patent/MX389553B/es unknown
- 2017-01-13 SG SG11201805791RA patent/SG11201805791RA/en unknown
- 2017-01-13 ES ES17738695T patent/ES2946945T3/es active Active
- 2017-01-13 CN CN202511095689.5A patent/CN120661527A/zh active Pending
-
2018
- 2018-07-13 MX MX2022000945A patent/MX2022000945A/es unknown
-
2022
- 2022-08-12 JP JP2022128627A patent/JP7467543B2/ja active Active
-
2024
- 2024-04-03 JP JP2024059854A patent/JP2024081767A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210079376A (ko) | 2021-06-29 |
| EP3403655A4 (en) | 2019-08-07 |
| CN120661527A (zh) | 2025-09-19 |
| US20190030053A1 (en) | 2019-01-31 |
| CN108472305A (zh) | 2018-08-31 |
| WO2017123066A1 (ko) | 2017-07-20 |
| JP2022166164A (ja) | 2022-11-01 |
| MX2022000945A (es) | 2022-02-14 |
| SG11201805791RA (en) | 2018-08-30 |
| ES2946945T3 (es) | 2023-07-28 |
| MX389553B (es) | 2025-03-20 |
| KR20180099885A (ko) | 2018-09-05 |
| EP3845233A1 (en) | 2021-07-07 |
| MX2018008671A (es) | 2019-02-13 |
| KR20230107718A (ko) | 2023-07-17 |
| JP2019502718A (ja) | 2019-01-31 |
| JP7125348B2 (ja) | 2022-08-24 |
| CA3010338C (en) | 2023-08-22 |
| JP2024081767A (ja) | 2024-06-18 |
| CA3010338A1 (en) | 2017-07-20 |
| RU2018128408A (ru) | 2020-02-13 |
| CN120643579A (zh) | 2025-09-16 |
| EP3403655C0 (en) | 2023-06-07 |
| EP3403655B1 (en) | 2023-06-07 |
| HK1257689A1 (zh) | 2019-10-25 |
| KR102771814B1 (ko) | 2025-02-26 |
| JP7467543B2 (ja) | 2024-04-15 |
| RU2018128408A3 (enExample) | 2020-02-13 |
| CA3203927A1 (en) | 2017-07-20 |
| EP3403655A1 (en) | 2018-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY197561A (en) | Composition for increasing expression of pgc-1? | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX390302B (es) | Oxiesteroles y metodos de uso de los mismos | |
| BR112018003026A2 (pt) | composições compreendendo um inibidor de pi3k e um inibidor de hdac | |
| MX375484B (es) | Derivados de azabencimidazol como inhibidores de pi3k beta | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| TN2017000075A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| MY194468A (en) | Oxy-fluoropiperidine derivatives as kinase inhhiitor | |
| MX2020010690A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| EA201990833A1 (ru) | Соединение пиридина | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| EA201992542A1 (ru) | Фармацевтическая композиция для местного применения, содержащая, по меньшей мере, амитриптилин, для лечения периферической нейропатической боли | |
| MX2022007670A (es) | Compuestos antihelminticos que comprenden una estructura de quinolina. | |
| MX382175B (es) | Composiciones de profármaco de monometilfumarato | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| MX2016014939A (es) | Derivados de carboxamida. | |
| MX388592B (es) | Compuestos y metodos terapeuticos. | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| PH12021550304A1 (en) | Novel medicament for treating inflammatory bowel disease | |
| MX2020004842A (es) | Compuestos heterociclicos antiinfecciosos y sus usos. | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| JOP20200030A1 (ar) | مركب خماسي الحلقة | |
| MX379576B (es) | Derivados de azetidina | |
| MX2018016339A (es) | Compuestos heterociclicos antiinfecciosos y sus usos. |